about
Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolatesSiderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteriaCharacterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas.Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.Effect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of ETX0914.Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/β-lactam combinations.Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteriaMicrobiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes.Multicity outbreak of linezolid-resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain.Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014).Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014).A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility TestingGeographic and Temporal Patterns of Antimicrobial Resistance in Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997-2016In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programmeAntimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor ZoliflodacinSurveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor EnmetazobactamIn Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America665. In vitro Activity of Omadacycline Against Recent (2018) Bacterial Pathogens from the United States and Europe Obtained from Skin and Skin Structure, Respiratory, and Urinary Tract Infections
P50
Q27684005-46B1760A-3661-4A61-A6A0-DD3799F52D78Q27689683-BA2173D9-3992-4F50-9873-569353246BF3Q35076809-66F4E72D-C6B2-42B3-9B53-1E7CFE251C5AQ35607663-5625AEFF-943C-4F57-BE43-3A3BD0964671Q35848139-5F989FEB-2B2E-41CC-80AE-8E216E9B36AFQ37843405-50D057EE-5948-4FDA-B8DD-2DB747D49D49Q39180287-33317AC1-CC43-4C48-974A-0C53C6A94080Q39513210-75961194-5577-4A42-A5C3-60070AEDBB30Q40173929-A9889423-20F1-4F1F-9AE8-18FC460BB387Q40315631-BAF5B278-C7EB-4F6B-93FF-7C5C48AFCEA2Q41561999-2079DD76-8372-4504-8755-8E0A4ABEDBA2Q41668866-23E3BAF8-C71C-4D6B-94B8-5C955BCD2DCBQ41712144-B8DF180F-1BF0-4C7D-A46A-8BF4C1D7DA74Q42931166-A332DBA7-D3A0-4A0F-A334-D31CF45C7473Q54249697-B7C11AD5-7C9E-4478-8BA1-A49449D8D143Q54313791-FA0E4DED-32A1-4764-993D-2B642D178EC4Q58088798-93EAF7FA-205C-4F8D-B7BD-1F8B5D4F3A39Q64089828-FE0742C9-9C8B-4EC0-A176-CF4BC29E5A6BQ87979095-8CA986F6-3C21-45F3-B9F4-38B1674B0A1BQ90928438-8DF7FFCB-C072-4158-ADB5-5B599178A98AQ91967165-74E2D56D-E5BC-4D4B-BCEE-602C9BC59943Q92069475-F8913165-FB05-4633-8E4A-ED25DF8D2B0CQ92546819-14FBB950-6253-410B-997B-CBA3B7B0160CQ92641250-6DBE065F-28E8-4401-A425-69806275E6FAQ93242524-FDA5FEB3-0BFC-455B-BBEF-083ECFFD70ECQ94144273-1756E8D4-C535-45B5-9EB9-D59DC8E3E09D
P50
description
investigador
@es
researcher
@en
name
Michael D Huband
@en
type
label
Michael D Huband
@en
prefLabel
Michael D Huband
@en
P108
P31
P496
0000-0002-9769-9019